DOI: 10.1002/hsr2.327

REVIEW

Revised: 4 May 2021

Health Science Reports

WILEY

The effects of genetic polymorphisms on benzene-exposed workers: A systematic review

Verónica Ramírez-Lopera¹ Henry Bautista-Amorocho^{1,2} Enrique Mateus-Sánchez³

¹Bacterias & Cáncer Group, Microbiology and Parasitology, Faculty of Medicine, Universidad de Antioquia, Medellín, Colombia

²Grupo de Investigación en Desarrollo Humano, Tejido Social e Innovaciones Tecnológicas—GIDTI, Programa Administración en Salud Ocupacional, Centro Regional Bucaramanga, Corporación Universitaria Minuto de Dios, Bucaramanga, Colombia

³Grupo de Investigación en Desarrollo Humano, Tejido Social e Innovaciones Tecnológicas—GIDTI, Programa de Psicología, Centro Regional Bucaramanga, Corporación Universitaria Minuto de Dios, Bucaramanga, Colombia

Correspondence

Verónica Ramírez-Lopera, Cra. 51d #62-29, Medellín 050010, Antioquia, Colombia. Email: veronica.ramirezl@udea.edu.co

Funding information

Ministerio de Ciencia, Tecnología e Innovación, Grant/Award Number: COL126780763345/ Contract RC.847-2019 Daniel Uribe-Castro¹
 Jorge Alexander Silva-Sayago²
 Wilman Yesid Ardila-Barbosa²
 Tania Liseth Pérez-Cala¹

Abstract

Background and Aims: Benzene is a group I carcinogen, which has been associated with leukemia and myelodysplastic syndrome. Moreover, it has been proposed that polymorphisms in benzene metabolizing genes influence the outcomes of benzene exposure in the human body. This systematic review aims to elucidate the existent relationship between genetic polymorphisms and the risk of developing adverse health effects in benzene-exposed workers.

Methods: Three databases were systematically searched until April 2020. The preferred reporting items for systematic reviews and meta-analyses method was used to select articles published between 2005 and 2020. Quality assessment and risk of bias were evaluated by the Newcastle-Ottawa scale.

Results: After full-text evaluation, 36 articles remained out of 645 initially screened. The most studied health effects within the reviewed papers were chronic benzene poisoning, hematotoxicity, altered urinary biomarkers of exposure, micronucleus/ chromosomal aberrations, and gene methylation. Furthermore, some polymorphisms on NQO1, GSTT1, GSTM1, MPO, and CYP2E1, among other genes, showed a statistically significant relationship with an increased risk of developing at least one of these effects on benzene-exposed workers. However, there was no consensus among the reviewed papers on which specific polymorphisms were the ones associated with the adverse health-related outcomes, except for the NQO1 rs1800566 and the GSTT1 null genotypes. Additionally, the smoking habit was identified as a confounder, demonstrating worse health outcomes in exposed workers that smoked.

Conclusion: Though there is a positive relationship between genetic polymorphisms and detrimental health outcomes for benzene-exposed workers, broader benzene-exposed cohorts that take into account the genetic diversity of the population are needed in order to determine which specific polymorphisms incur in health risks.

Institution at which the work was performed: Universidad de Antioquia, Facultad de Medicina, Medellín, Antioquia, Colombia.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2021 The Authors. *Health Science Reports* published by Wiley Periodicals LLC.

KEYWORDS

benzene, chronic benzene poisoning, genetic polymorphisms, hematotoxicity, occupational health

1 | INTRODUCTION

Benzene is an important chemical and ubiquitous environmental pollutant usually used as a solvent in industrial environments (eg, petrochemical industry, steel plants, shoe manufacturing, etc.). Moreover, it is an important toxicant, given that it is the main component of cigarette smoke, gasoline, crude oil, and automotive emissions.¹⁻⁴ Benzene is classified by the International Agency for Research on Cancer (IARC) as a group I human carcinogen⁵; furthermore, it is the cause of several hematological disorders, such as anemia, leukopenia, thrombocytopenia, acute myeloid and lymphocytic leukemia, myelodysplastic syndrome, and non-Hodgkin lymphoma.⁶

The toxicity of benzene has been related to its metabolism, which is illustrated in Figure 1. After benzene inhalation, a number of reactions occur, which involve different enzymes such as NADPH quinone oxidoreductase-1 (NQO1), myeloperoxidase (MPO), gluta-thione S-transferases (GST), hydrolases and CYP enzymes (mainly CYP2E1).^{2,6-8} These metabolic pathways produce metabolites that are excreted in the urine, for instance *trans,trans*-muconic acid (t,t-MA) and S-phenylmercapturic acid (S-PMA). Additionally, enzymes like NQO1 or GSTs catalyze detoxification reactions.^{2,7}

Even though the mechanisms by which benzene exerts its genotoxic and hematotoxic effects have not yet been fully elucidated,⁸ it is widely accepted that benzene reactive intermediates can bind covalently to macromolecules including DNA, tubulin, histories, and topoisomerase II in the tissue. Furthermore, the resultant metabolites are produced in conjunction with reactive oxygen species, and therefore, cause oxidative stress and subsequent genotoxicity. This results in cell damage and DNA double-strand breaks; thus, altering the normal cell cycle, generating carcinogenic effects on the bone marrow and the lympho-hematopoietic system. It has also been proposed that this aromatic hydrocarbon can produce direct damage to hematopoietic progenitor cells, which could lead to apoptosis or altered responsiveness to cytokines and cellular adhesion molecules.^{7,9-11} Moreover, benzene toxicity to mature blood cells or stromal cells could disrupt the regulation of hematopoiesis, including maturation, hematopoietic commitment, or mobilization, through the network of chemokines, adhesion molecules, and cytokines.⁸

As mentioned above, industrial environments are an important source of benzene exposure, with workers in major industry sectors (such as petrochemical plants, petroleum refineries, coke and coal chemicals or tire manufacturers) exposed to ranges that vary from 0 to 0.325 mg/m³ to more than 32.5 mg/m³ of benzene, contrasting the environmental exposure of the general population that varies from 0.0028 to 0.04 mg/m^{3.12,13} Consequently, international agencies have set occupational exposure limits in order to reduce the risk for adverse health outcomes in subjects exposed to this hydrocarbon at their workplace.^{14,15} Nonetheless, uniformity between these guide-lines when establishing occupational exposure limits is lacking,¹⁴⁻¹⁷ especially considering that some individual factors such as genetic

diversity predispose the population to benzene-related adverse health effects, even at low levels of exposure.¹⁸

For example, several studies have reported a relationship between polymorphisms of benzene-metabolizing enzymes and higher susceptibility to benzene toxicity.¹⁸⁻²² Dougherty et al, De Palma et al, and Carbonari et al reviewed, in 2008, 2014, and 2016, respectively, the effect of genetic polymorphisms on biomarkers of exposure and biomonitoring, among benzene-exposed workers.^{8,10,23} However, since then, new studies have surfaced, and a review that includes benzene health-related effects other than biomarker excretion is in order. Consequently, in this systematic review, we aim to elucidate the existent relationship between genetic polymorphisms and the risk of developing adverse health outcomes in benzeneexposed workers.

2 | METHODS

2.1 | Search strategy

A systematic search, based on preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines,²⁴ was conducted on Scielo, Pubmed, and Medline databases using Boolean operators, Medical Subjects Heading (MeSH), and non-MeSH terms: *Benzene, occupational, mutations, and polymorphism.* The full search strategy was adapted for each database and is listed on the Supporting Information.

2.2 | Study eligibility criteria

We only included studies that evaluated the effect of at least one polymorphism in different variables, with human subjects older than 18, whose main source of benzene exposure was occupational. We also exclusively added papers written in English or Spanish. Additionally, we filtered the results by only using articles published from 2005 to April 2020. Papers that only focused on environmental exposure were rejected, as were in-vitro studies. The accepted types of research were solely observational studies such as cross-sectional and case-control studies.

2.3 | Study selection

Article selection was conducted independently by two reviewers (VR-L and DU-C), and this process is illustrated in Figure 2.²⁴ The first search retrieved 645 results, and after the application of two filters (year-of-publication and not-in-vitro-studies), followed by narrowing of the search strategy with the use of Boolean operators (see




FIGURE 1 Metabolic pathways of benzene. ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; CYP, cytochrome P-450; DHDH, dihydrodiol dehydrogenase; EPHX1, microsomal epoxide hydrolase 1; GST, glutathione S-transferase; MPO, myeloperoxidase; NQO1, NAD(P)H quinone dehydrogenase 1

Supporting Information), 549 papers were excluded. We added 21 cross-references to the remaining 96 articles, found either on the searched databases or on the remaining-papers references. Those articles were then screened by their titles, and 35 duplicates as well as nine titles that fulfilled the exclusion criteria were excluded. The results of the search were imported to the Zotero software, which was used as a reference manager. Afterward, two reviewers analyzed whether or not the abstracts met the inclusion criteria previously established, and then the same procedure was conducted with the full-text articles. If there was a disagreement, a third reviewer (TLP-C) resolved it. After that, 36 papers were included. To avoid the omission of articles relevant to the research, the references included in the reviewed articles were compared and checked.

2.4 | Data extraction

A table was created for summarizing the following characteristics from each paper: authors and year of publication, country of publication, sample size, age, gender, evaluated variable, evaluated genes and polymorphisms, quality assessment, and relevant results. The mean summary measures used in this review were odds ratios (OR), adjusted odds ratios (ORadj), *P* values (*P*), risk ratios (RR), and frequency ratios (FR).

2.5 | Protocol and study quality assessment

This systematic review was indexed in the prospective register of systematic reviews (PROSPERO). To assess the quality of these studies, the Newcastle-

4 of 26 WIL FY_Health Science Reports






FIGURE 2 PRISMA search strategy flowchart

Ottawa Scale (NOS) was modified to fit each study type, as stated on the Supporting Information.²⁵ For case-control studies, three categories were evaluated: selection, comparability, and exposure; for cross-sectional studies, the exposure category was replaced with "outcome." Points were assigned according to the study's quality and bias risk, the maximum number of points each study could get was 9. The higher the number of points, the lower the bias risk was (see Supporting Information, Appxs. B-E).

3 | RESULTS

3.1 | Characteristics of eligible studies

A total of 36 articles were retrieved from the conducted systematic search, six were cross-sectional studies and 30 were casecontrol studies. All of them assessed occupationally benzeneexposed population and evaluated one or more of the following benzene effects: chronic benzene poisoning (CBP), hematotoxicity, altered urinary biomarkers, micronucleus/chromosomal aberrations (CA), and gene methylation. Regarding the NOS, both case-control and crosssectional studies reached an average of 6 points out of 9, the former ranging from 5 to 8, and the latter from 5 to 7. These results are summarized in Table 1.

3.2 | Effects of polymorphisms on susceptibility to CBP

There were 10 studies that researched the relationship between polymorphisms and CBP (see Table 2).

			Open Access		
Quality assessment score	8/8	6/9	6/9	5/9	(Continues)
Results	 Increased WBC count was evidenced in exposed workers with: VEGF rs3025030 (variant allele C; P < 0.001) VEGF rs833058 (variant allele C; P = 0.0011) Homozygous variant alleles of rs3025030 - rs833058 ERCC3 rs4150441 (variant allele T; P = 0.0086) ERCC3 rs6731176 (variant allele C; P = 0.0087) 	Increased risk of CBP in non-smokers with: ERCC1 rs11615 (TT genotype) [OR = 3.21 (95% CI 1.36-7.60), P = 0.006]	 Increased risk of CBP in individuals with: <i>p14ARF</i> TGA/TAG diplotype (<i>P</i> = 0.0006) Decreased risk of CBP in individuals with: <i>p14ARF</i> rs3731245 (GA + AA genotypes) [ORadj = 0.57 (95% CI 0.36-0.89)] <i>p14ARF</i> TGG/TAA diplotype (<i>P</i> < 0.001) <i>p14ARF</i> TGG/TAA diplotype (<i>P</i> < 0.001) <i>p14ARF</i> TGG/TAA diplotype (<i>P</i> < 0.001) <i>p14ARF</i> rs3731245 (GA + AA genotypes) [ORadj = 0.25 (95% CI 0.10-0.62), <i>P</i> = 0.003] 	Decreased risk of CBP in individuals with: • p21 rs1801270 (CA + AA genotype) [OR = 0.51 (95% CI 0.32-0.83)] rs1059234 (CT + Π genotype) [OR = 0.53 (95% CI 0.29-0.95)]	
Genes and polymorphisms studied	VEGF rs3025030 rs83058 rs69946 ERCC3 rs4150441 rs6731176 Other genes: BLM, GPX3, IL8RB/IL8RA, RIPK2, IL6, IL6R, IL10/IL19, IL12RB1, WRN, IFNAR2	ERCC1 rs11615 rs2212986 ERCC2/ XPD rs13181 rs1799793 rs238406	GADD45A p14AR rs581000 rs3731217 rs11544978 rs3731245 rs532446 rs3088440 MDM2 Del1518 Del1518 Del1518	TP53 rs17878362 rs1042522 rs1625895 p21 rs1801270 rs1059234	
Evaluated variable*	Total WBC count	Risk of developing CBP	Risk of developing CBP	Risk of developing CBP	
Mean benzene exposure	Exposed workers: 5.4 ppm (SD 12.1 ppm) Unexposed controls: <0.04 ppm	1	1	1	
Participants (age range or mean [in years], gender)	21.5-39.03 y. o. 252 female 252 female	18-63 y.o. 63 male 243 female	18-68 y.o. 379 male 219 female	18–68 y.o. 440 male 280 female	
Sample size	250 workers exposed to benzene 140 unexposed controls	102 patients with CBP 204 patients without CBP	303 benzene-poisoned patients 295 workers occupationally exposed to benzene (controls)	345 benzene-poisoned patients 336 (controls) 37 non-exposed workers	
Country	China	China	China	China	
Authors and year of publication	Hosgood et al ²⁶	Xiao et al ²⁷	Sun et al ¹¹	Sun et al ²⁸	

 TABLE 1
 Characteristics of the included studies

23988835, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/hsr2.327 by Cochrane Colombia, Wiley Online Library on [2209/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Quality assessment score	2/9	6/9	5/9	6/9	6/9
Results	None of the investigated polymorphisms was related with blood cell count	No significant differences were found between DNA damage, urinary phenol level and the polymorphisms evaluated	XRCC1 rs25487 (399Gln allele) had a lower DNA repair-capacity than those with 399Arg/Arg genotype (<i>P</i> < 0.01, in laboratory workers only) CYP2E1*1/*5 and CYP2E1*5/*5 genotypes had lower benzene levels in blood than those with the CYP2E1*1/*1 genotype (in laboratory workers only) NQO1 and GST71 genotypes: no effects on t,t-MA levels	 More susceptibility to CBP in subjects with: CYP1A1 rs4646903 (TT genotype) [ORadj = 1.21 (95% CI 1.03-1.42), P < 0.05] CYP2D6 rs1065852 (CC or CT genotypes) [ORadj = 2.11 (95% CI 1.22-3.65), P < 0.05] CYP2D6 rs1135840 (CC genotype) [ORadj = 1.69 (95% CI 1.04-2.74), P < 0.05] 	 Higher risk of CBP with: hMTH1 83Val/Met + Met/Met hMTH1 83Val/Met + Met/Met [ORadj = 2.47 (95% CI 1.03-5.92)] compared to Val/Val (only in non-smokers) hOGG1 326Cys/Cys hOGG1 326Cys/Cys [ORadj = 3.06 (95% CI (1.74-5.35)] compared to Ser/Ser + Ser/Cys (Cys (only in non-smokers)
Genes and polymorphisms studied	NQO1 rs1800566 CYP2E1 rs2031920 (Rsal) rs6413432 (Dral)	CYP2E1 rs3813867/rs203192 (Pstl/Rsal) rs6413432 (Dral) GSTT1 Null and no null GSTM1 Null and no null	CYP2E1 CYP2E1*1/*5 CYP2E1*1/*1 CYP2E1*1/*1 NQO1 rs1800566 GSTT1 Null and no null XRCC1 rs25487	CVP1A1 UGT1A6 rs4646903 c.181 T > A CVP2D6 UGT1A7 rs1065852 208Trp > Arg rs1135840 SULTA1 c. 212 G > A c.638G > A	hMTH1 rs4866 (Val83Met) hOGG1 rs1052133 (Ser326Cys) hMYH rs3219489 (His324Gln)
Evaluated variable*	Total blood cell count	DNA damage and urinary biomarker PH	DNA repair- capacity, blood biomarkers (blood benzene levels) and urine biomarkers (t.t- MA)	Risk of developing CBP	Risk of developing CBP
Mean benzene exposure	1.71 ppm	1	Laboratory workers: 24.4 ppb Gasoline service attendants: 112.41 ppb Controls: 1.39 ppb	40 mg/m ³ : Cases: 18.4% Controls: 21.7% 41-100 mg/m ³ : Cases: 61.2% Controls: 61.8% > 100 mg/m ³ Cases: 20.4% Controls: 16.5%	40 mg/m ^{3;} Cases: 18.4% Controls: 21.7% 41-100 mg/m ³ >100 mg/m ³ Cases:20.4% Controls: 16.5%
Participants (age range or mean [in years], gender)	30.5-52.1 y. o. 171 male 32 female	19-56 y.o. 65 male 25 female	16-60 y.o. 87 male 9 female	19-61 y.o. 118 male 186 female	19–61 y.o. 118 male 186 female
Sample size	158 petrochemical workers exposed to benzene 50 unexposed subjects	30 directly exposed and 60 without occupational exposure	62 cases 34 controls	152 benzene poisoning patients152 control workers (occupationally exposed to benzene)	152 benzene poisoning patients152 control workers (occupationally exposed to benzene)
Country	Bulgaria	Colombia	Thailand	China	China
Authors and year of publication	Pesatori et al ²⁹	Torres et al ³⁰	Chanvaivit et al ³¹	Gu et al ³²	Wu et al ³³

TABLE 1 (Continued)

(Continued)	
-	
Щ	
Ω	
ΓA	

AIREZ-LOPERA EI	AL.			
	1			
Quality assessment score		6/9		6/9
Results	 hMTH1 83Val/Val and hOGG1 326Cys/Cys at the same time [ORadj = 2.57 (95% CI 1.49- 4.42), P < 0.01] Lower risk of CBP with: hMYH 324His/Gln + Gln/Gln [ORadj = 0.15 (95% CI 0.03-0.68)] (only in smokers) 	Higher risk of CBP with: -XRCC1 rs25489 *Arg/His [ORadj = 1.67 (95% Cl 1.02-2.74), P = 0.04] compared to Arg/Arg Arg/His-His/His in non-smokers [ORadj = 1.96 (95% Cl 1.14-3.38)] and non-alcohol users [ORadj = 1.78 (95% Cl 1.05- 3.03] only Haplotypes of XRCC1 *194Arg, 280His and 399Arg [ORadj = 2.96 (95% Cl 1.60-5.49), P = 0.001]	 Lower risk of CBP with: XRCC1 rs1799782 *Arg/Trp + Trp/Trp [ORadj = 0.60 (95% CI 0.37-0.98), P = 0.041] compared to Arg/Arg APE1 rs1130409 *Asp/Glu + Glu/Glu in alcohol users [ORadj = 0.11 (95% CI 0.02-0.69)] 	 Higher risk of CBP with: XRCC1 rs25487 (AA genotype) [ORadi] = 14.89 (95% CI 6.54- 30.21), P < 0.001] XRCC1 rs1799782 (TT genotype): only in alcohol drinkers [OR = 8.0 (95% CI 1.32-48.64), P = 0.022], males [OR = 9.33 (95% CI 1.59- 54.67), P = 0.019] and < 12 year exposure [OR = 2.61 (95% CI 1.05-6.51), P = 0.035]
Genes and polymorphisms studied		ADPRT rs1136410 (Val762Ala) XRCC2 rs3218536 (Arg188His) XRCC3 rs861539 (Thr241Met)		XPB/ERCC3 rs4150441 XPC rs2228001 rs227901 XPF rs4781560
Genes and polym		XRCC1 rs1799782 (Arg194Trp) rs25489 (Arg280His) rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25489 rs25487 rs25489 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs25487 rs2647 rs264		XRCC1 rs25487 rs25489 rs1799782 CD3EAP rs96759 PPP1K131 rs1005165
Evaluated variable*		Risk of developing CBP		Risk of developing CBP
Mean benzene exposure		40 mg/m ^{3;} Cases:18.4% Controls: 21.7% 41-100 mg/m ³ : Cases: 61.2% >100 mg/m ³ Cases: 20.4% Controls: 16.5%		1
Participants (age range or mean [in years], gender)		19-61 y.o. 118 male 186 female		18–63 y.o. 63 male 243 female
Sample size		152 benzene poisoning patients152 control workers(occupationally exposed to benzene)		102 CBP patients 204 controls
Country		China		China
Authors and year of publication		Zhang et al ³⁴		Xue et al ³⁵

(Continues)

Quality assessment score		2/9	6/2	6/9
Results	 XPB/FRCC3 rs4150441: GA [OR = 1.73 (95% CI 1.00-2.99), P = 0.049] and GA + AA genotypes [OR = 1.72 (95% CI 1.01-2.9), P = 0.043] compared to GG genotype Lower risk of CBP in males with: PPP1R13L rs1005165 (CT, TT and CT + TT genotypes) (P < 0.05) CD3EAP rs967591 (GA and GA + AA genotypes) (P < 0.05) 	Lower S-PMA and higher t.tMA/S- PMA ratio in subjects with <i>GSTT1</i> null genotype (compared to no null genotype) (P < 0.001) Lower S-PMA and higher t.tMA/S- PMA ratio in subjects with <i>GSTM1</i> null genotype compared to no null genotype (P < 0.001, only in smokers)	G5TM1 null genotype was associated with changes related to CBP (ie, symptoms, altered MCV and neutrophil %) [OR = 5.13 (95% CI 1.13-23.15)]	ERCC3 showed an increased methylation level in exposed workers ($P = 0.048$) Increased number of C allele for EPHX1 rs1051740 was associated with decreased methylation level of the ERCC3 gene in exposed workers ($P = 0.001$) Reduced WBC count was associated with increasing number of G allele for EPHX1 rs2234922 in exposed workers ($P = 0.044$) Increasing number of C allele for cPY1A1 rs4646903 in exposed workers ($P = 0.001$)
Genes and polymorphisms studied		GSTP1 Is1695 GSTM1 Null and no null GSTT1 Null and no null	CYP2E1 GSTM1 rs2031920 Null and no null rs6413432 GSTT1 NQO1 Null and no null rs1800566 MPO rs2333227 rs2333227	CYP1A1 1s4646903 EPHX1 1s1051740 1s2234922 NQ01 1s1800566 Methylation levels of: BLM, CYP1A1, EPHX1, ERCC3, NQ01, NUD71, p15, p16, RAD51, TP53, and WRAP53
Evaluated variable* G		Urinary G biomarkers: S- PMA, tt-MA and t,t-MA/S- N PMA ratio N	Risk of developing C CBP rst	Altered DNA methylation and total WBC count N N N N
Mean benzene exposure		0.0368 mg/m ³ (0.01 ppm)	1	For 34 exposed workers: 324 ppm-years For 43 exposed workers: >100 ppm-years
Participants (age range or mean [in years], gender)		23-65 y.o. 309 male 6 female	19-82 y.o. 87 male 27 female	43-67 y.o. 38 male 64 female
Sample size		 181 occupationally exposed petrochemical workers (cases) 134 administrative employees (controls) 	 114 gas-station attendants: 72 with clinical findings (CF) 52 with no clinical findings (NCF) 	77 benzene-exposed workers 25 unexposed controls
country		Italy	Brazil	China
Authors and year of publication		Mansi et al ⁴	Mitri et al ³⁶	Xing et al ³⁷

(Continued)

TABLE 1

 			Open AccessWILEY
Quality assessment score	7/9	2/9	7/9 (Continues)
Results	Higher t.t-MA in exposed subjects with at least one variant allele in CYP2E1 rs6413432 (P = 0.03) Reduced U-benzene excretion in subjects with at least one mutant allele of CYP2E1 rs2031920 (P < 0.01) All the biomarkers were influenced by smoking	Subjects bearing the NQO1*1*1 (wild- type genotype) showed lower levels of oxidative damage to RNA compared to subjects with at least one variant allele ($P < 0.05$) Lower S-PMA excretion with GSTM1 null ($P = 0.01$), GSTT1 null ($P = 0.048$) genotypes compared to positive genotypes In subjects defective for one GST enzyme, the other one could effectively play a vicarious activity	Higher risk of CBP in: -EPHX1 GGAC/GAGT ($P = 0.00065$) or AGAC/GAGT ($P = 0.00086$) diplotypes Decreased risk of CBP in G5TP1 rs1695 (AG + GG genotype) [OR = 0.44 (95% CI 0.24-0.81), P = 0.007] only in non-alcohol drinkers With: EPHX1 rs3738047 (GA + AA with: EPHX1 rs3738047 (GA + AA genotype [OR = 5.0 (95% CI 0.89- 30.52), $P = 0.073$] compared to GG genotype Decreased risk of CBP in alcohol drinkers with: EPHX1 rs2234922 AG + GG compared to GG ($P = 0.008$) or rs1051741 CT + TT compared to CC ($P = 0.043$)
Genes and polymorphisms studied	CYP2E1 rs2031920 (Rsal) rs6413432 (Dral) NQO1 Polymorphism not specified	NQ01 1s1800566 NQ01'1'1 NQ01'1'2 GSTM1 Null and no null GSTA1 'A'B GSTA1'A'B GSTA1'B'B GSTA1'B'B	CYP1A1 NQO1 rs4646421 rs1800566 MPO rs4646422 rs1800566 MPO rs4646422 rs1800566 MPO rs1800566 MPO rs208693 rs1048943 rs1800566 MPO rs4646422 rs1800566 MPO rs4646423 rs180566 MPO rs4646903 rs1695 cYP1A2 rs105892 rs2445618 rs6786892 rs2472304 rs4124874 rs24728040 rs3755319 rs24708900 rs3755319 rs2470890 rs3755319 rs2470890 rs3755319 rs2470890 rs3755319 rs2470890 rs3755319 rs2470890 rs3755319 rs2470890 rs3753319 rs2470891 rs3753319 rs247181 rs3753319 rs247481 rs3753319 rs247481 rs3753319 rs27239451 rc7P1A1 rs2234922 UGT1A6 rs2234922 UGT1A6 rs2051741 rs781141
Evaluated variable* Gen	Urinary CYP2E: biomarkens: S- rs2031 PMA, tt-M, U- rs6413 benzene and U- NQO1 cotinine Polym	Urinary NQ01 biomarkers: S- rs18000 PMA, tt-MA NQ01* and biomarkers NQ01* of nucleic acid G5TM1 oxidation: Null and 8-oxoGuo, G5TA1 8-oxoGua and Null and 8-oxoGua G5TA1* G5TA1* G5TA1*	Risk of developing CYP1A, CBP rs4646 rs4646 rs10487 rs26456 CYP18; rs26456 AD546 rs10561 rs20547 rs20557 rs205
Mean benzene exposure	Gas station attendants: 61 μg/m ³ Urban policemen: 22 μg/m ³ Bus drivers: 21 μg/m ³ Controls: 7.5 μg/m ³	38.3 µg/m ³	40 mg/m ³ : Cases: 53.7% Controls: 55.6% 41-100 mg/m ³ : Cases: 34.7% Controls: 35.1% >100 mg/m ³ Cases: 11.6% Controls: 9.3%
Participants (age range or mean [in years], gender)	28.9-48.1 y. o. 63 female	27.7.54.5 y. o. 69 female	17-68 y.o. 342 male 194 female
Sample size	308 cases (urban policemen, gas station attendants and bus drivers) 107 controls	239 workers (taxi drivers, traffic policemen and gasoline pump attendants)	248 benzene-poisoned patients 268 workers occupationally exposed to benzene
Country	Italy	Italy	China
Authors and year of publication	Fustinoni et al ²	Manini et al ⁵	Sun et al ³⁸

TABLE 1 (Continued)

(Continued)
-
щ
B
4

Quality assessment score	6/9	8/9
Results	 Higher risk of CBP in: NQO1 rs1800566 TT genotype [OR = 2.82 (95% CI 1.42-5.58)] compared to CT + CC genotypes GSTT1 null genotype [ORadj = 1.91 (95% CI 1.05-3.45)] NQO1 rs1800566 TT genotype plus GSTT1 null genotype [OR = 4.59 (95% CI 1.73-12.20)] compared to CT + CC plus no null genotypes NQO1 rs1800566 TT genotype plus GSTT1 null [OR = 16.13 (95% CI 3.15-83.33) NQO1 rs1800566 CT + CC genotype plus GSTT1 null genotype plus GSTT1 null 	Decreased WBC count in exposed workers with: IL-1A rs1800587 CT + Π genotype ($P < 0.001$) compared to CC IL-4 rs2243248 TG genotype ($P = 0.0046$) compared to Π IL-10 rs1800871 CC genotype ($P = 0.0034$) compared to Π IL-12A rs568408 AA genotype ($P = 0.0034$) compared to Π IL-12A rs568408 AA genotype ($P = 0.0024$) compared to Π IL-12A rs568408 AA genotype ($P = 0.0022$) compared to Π IL-12A rs568408 AA genotype ($P = 0.0022$) compared to Π IL-12A rs568408 AA genotype ($P = 0.0022$) compared to Π Increased WBC count in exposed workers with: CSF3 rs1042658
orphisms studied		IL-10 rs1800871 IL-12A IL-12B rs568408 IL-12B rs20541 IL-16 rs20541 IL-16 rs20541 IL-16 rs2053 TNF rs1799864 rs17799864 CCR5 rs17799864 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs2734648 IL-8 rs274673
Genes and polymorphisms studied	NQ01 rs1800566 MPO rs2333227 CYP2E1 rs2031920 rs6413432 GST71 Null and no null GST71 Null and no null	ICAM1 155491 155491 VCAM1 151041163 153176879 1531042658 151469149 151469149 16-18 16-18 16-18 16-18 16-18 16-243248 16-4 16-2 16-4 16-2 16-4 16-2 16-4 16-2 16-4 16-2 16-4 16-2 16-4 16-2 16-4 16-2 16-2 16-2 16-2 16-2 16-2 16-2 16-2
Evaluated variable*	Risk of developing CBP	Total WBC count
Mean benzene exposure	1	Exposed workers: 5.4 ppm (SD 12.1 ppm) Unexposed controls: <0.04 ppm
Participants (age range or mean [in years], gender)	37 male 63 female	21.5-39.03 yo 252 female
Sample size	100 workers with CBP 90 controls	250 workers exposed to benzene 140 unexposed controls
Country	China	China
Authors and year of publication	Chen et al ³⁹	Lan et al ⁹

rs2069812

Quality assessment score	8/9	8/9	8/9	(Continues)
Results	 Decreased WBC count in exposed workers with: WRN WRN Homozygous variants in: rs4987236 (P = 0.0003), rs2725349 (P = 0.001), rs1800392 (P = 0.001), rs2725362 (P = 0.001) BRCA2 Homozygous for uncommon allele of: rs1801406 (P = 0.045) 	 Decreased granulocyte, lymphocyte, and monocyte population counts in: VCAM1 rs3176867 (P < 0.0001) ALOX5 rs709968 (P = 0.0001) MPO rs2071409 (P = 0.0001) 	 Decreased WBC count in exposed subjects with: BLM rs2270132 (P = 0.00021), rs1694489 (P = 0.0038) and rs414634 (P = 0.0077) RAD51 rs4924496 (P = 0.00053) TP53 rs12951053 (P = 0.00029) and rs2230009 (P = 0.0002) WDR79 rs2287499 (P = 0.0005) 	
ohisms studied	BRCA2 rs1799943 rs1801406 rs543304 rs1709944 rs1799945 KRCC3 rs861539 KRCC3 rs861539 KRCC3 rs861539 rs861539 rs861539 rs1805377 rs1056503		RXRA rs1805352 BLM rs2270132 C5F3 rs3917979 RAD51 rs4924496 FFNB3 rs3744262 L10b rs1800871 MPD rs2071409 WDR79 rs17885803 rs17885803 rs17885803	
Genes and polymorphisms studied	WRN rs4987236 rs2723349 rs1800392 rs2725362 rs4987036 rs1346044 rs1042522 rs1042522 rs1692794 BRCA1 rs16940 rs799917 rs16941	MBP rs470261 VCAM1 rs1041163 rs3176867 ALOX5 rs4948671 rs7099684 MPO rs2071409 rs2071409 rs203773 rs2239773 rs2180094	APOB rs3791981 IGF2R rs1570070 IL1A rs17561 GSK3B rs1719888 WRN rs2230009 rs2725362 TP53 rs12951053 GPX3 rs8177426	
Evaluated variable*	Total WBC count	Total WBC count	Total WBC count	
Mean benzene exposure	Exposed workers: 5.4 ppm (SD 12.1 ppm) Unexposed controls: <0.04 ppm	0.36 ± 0.31 ppm	Exposed workers: 5.4 ppm (SD 12.1 ppm) Unexposed controls: <0.04 ppm	
Participants (age range or mean [in years], gender)	21.5-39.03 y.o. 138 male 252 female	21.5-39.03 y.o. 138 male 252 female	21.5-39.03 y.o. 138 male 252 female	
Sample size	250 workers exposed to benzene 140 unexposed controls	250 workers exposed to benzene 140 unexposed controls	250 workers exposed to benzene 140 unexposed controls	
Country	China	China	China	
Authors and year of publication	Shen et al ⁴⁰	Shen et al ¹	Lan et al ⁴¹	

TABLE 1 (Continued)

	Quality assessment score				
	Quality assessm score	6/2	6/9	6/9	6/9
	Results	 Decreased WBC counts in exposed subjects with: GSTT null genotype (P = 0.045) compared to no null genotype GSTM1 null genotype (P = 0.03) compared to no null genotype CYP2E1 rs2031920 CT genotype compared to CC (P = 0.020) and rs3813867 GC genotype 	Exposed workers with NQO1 TT genotype had increased MN [RR = 1.9 (95% Cl 1.5-2.3]] and CA [RR = 2.6 (95% Cl 1.7-3.9)] compared to those with CT or CC genotypes A rise in CA on subjects with MPO GG genotype [RR = 2.3 (95% Cl 1.3- 4.0]] and XRCC1 AA genotype [RR = 2.2 (95% Cl (1.5-3.1)] compared to those with MPO GA or AA and XRCC1 GG or AG respectively	Lower MN frequencies in exposed subjects with NQO1 TT genotype [FR = 0.79 (95% CI 0.66-0.95), P < 0.05] compared to the CC genotype	Higher MN frequency on workers with: -XRCC1 rs25487 AA genotype [FR = 1.50 (95% CI 1.16-1.9), P = 0.002] compared to GG; and GA genotype [FR = 1.20 (95% CI 1.06-1.37), $P = 0.006$] -APE1: rs1130409 GG genotype [FR = 1.28 (95% CI 1.05-1.55), P = 0.01] compared to TT; and GT genotype [FR = 1.20 (95% CI 1.04- 1.37), $P = 0.012$] -XPG rs17655 GC genotype [FR = 1.18 (95% CI 1.02-1.38), P = 0.038] compared to GG
	Genes and polymorphisms studied	GSTT1 Null and no null GSTM1 Null and no null Kalf95 rs1695 CYP2E1 rs3813867 rs2031920 rs6413432 rs3813867 rs2234922 rs3813667 rs2234922 rs1051740 rs2234922	NQ01 1s1800566 MPO 1s2333227 XRCC1 1s25487	NQO1 rs1800566 CVP2E1 rs3813867	XRCC1 XPC rs25489 rs2228000 rs25487 rs2228000 APE1 rs1130409 Frs228002 APE1 rs1130409 Frs228002 rs1799793 rs1799793 rs1799793 rs17655 FRCC1 rs3212986
	Evaluated variable*	Total WBC count	MN and CA	NX	MN and methylation
	Mean benzene exposure	6.4 mg/m³	0.51 ppm	Less than 0.6 mg/m³	6.4 mg/m³
	Participants (age range or mean [in years], gender)	19-57 y.o. 317male 288 female	30-52 y.o.	25.1-27.7 y. o. 65 female	17-71 y.o. 174 male 222 female
(p	Sample size	Cases: 385 exposed workers Controls: 220 healthy subjects	108 workers directly exposed to benzene 33 office workers	461 exposed workers 88 controls	294 benzene-exposed participants 102 controls indoor workers
(Continued)	Country	China	Korea	China	China
TABLE 1	Authors and year of publication	Ye et al ⁷	Kim et al ⁴²	Fang et al ⁴³	Zhang et al ⁴⁴

A.444.000	Participants
	(age range or
	mean [in
	years],
ublication Country Sample size	gender) Mean benzene exposure

¥				
Quality assessment score		8/8	8/8	6/2
Results	-ERCC1: rs3212986 TT genotype [FR = 1.55 (95% CI 1.31-1.83), P < 0.001] compared to GG Low global DNA methylation in subjects with APE1 rs1130409 GG + GT genotype (P = 0.045)	GSTT1 null was associated with lower platelet count ($P = 0.015$) and higher risk for hematological disorders [OR = 2.1 (95% CI 1.23- 3.56)] compared to GSTT1 positive Higher leukocyte counts with GSTM1 null compared to GSTM1 positive ($P = 0.026$)	NQO1 rs1800566 lowered tt-MA, S- PMA ($P = 0.001$), PH ($P = 0.022$), CAT ($P = 0.036$) and HQ ($P = 0.036$) CYP2E1 rs2031920 affected tt-MA ($P < 0.001$), PH ($P < 0.001$), HQ ($P < 0.001$) and S-PMA EPHX1 rs1051740 or ($P < 0.001$) and S-PMA EPHX1 rs1051740 or ($P < 0.001$) and S-PMA S37217 and I and G5771 and I lowered S-PMA ($P = 0.018$) MPO rs2333227 showed no effect on urinary biomarker excretion	Lower median S-PMA urinary concentration and a consequently higher t,t-MA/S-PMA (R value) in smokers with G5T1 null and G5TM1 null compared to no null genotypes (P < 0.05 for both genes) Higher R value in non-smokers with G5TT1 null compared to no null (P < 0.05)
orphisms studied				NQO1 rs1800566 CYP2E1 rs2031920 rs1048943 MPO rs2333227
Genes and polymorphisms studied		GSTP1 rs1695 CYP2E1 rs3813867 GSTM1 null and no null GSTT1 null and no null	CYP2E1 rs203192 NQO1 rs1800566 rs4986998 rs4986998 rs4986998 rs4986988 rs498494 rs947894 MPO rs2333227	GSTA1 rs3957356 GSTT1 Null and no null GSTM1 Null and no null EPHX1 rs67892231
Evaluated variable*		Total WBC count	Urinary biomarkers: t.t- MA, S-PMA, PH, CAT, and HQ	Urinary biomarkers: S- PMA, t,t-MA
Mean benzene exposure		Cases: 0.10 ± 0.195 ppm Controls: 0.12 ± 0.284 ppm	0.512 ppm	0.021 mg/m ³
(age range or mean [in years], gender)		27.62-40.9 y. o. All male	21-43 y.o. 248 males 138 females	30.6-53.4 y. o.
Sample size		Cases: 124 petrochemical plant benzene-exposed workers Controls: 184 subjects with a similar exposure scenario	250 benzene-exposed workers 136 control workers	301 oil refinery workers in Italy
Country		Iran	China	Italy
Authors and year of publication		Nourozi et al ⁶	Kim et al ³	Carbonari et al ⁴⁵

(Continues)

Quality assessment score		6/2	5/9	8/9	6/9
Results	 Lower median R value (higher S-PMA) in non-smokers with: NQO1 rs1800566 wild-type compared to heterozygous and mutant genotypes (P < 0.05) GSTA1 rs3957356 wild-type compared to heterozygous and mutant genotypes (P < 0.05) 	Increased MN frequency in subjects with DNMT3A rs1550117 variant allele (AG + AA) [FR = 1.19 (95% CI 1.05-1.36), $P = 0.003$] Lower global DNA methylation ($P = 0.094$) and higher MN frequency [FR = 1.18 (95% CI 0.99-1.40), $P = 0.054$] in subjects with DNMT3A (R882) variant allele (R882C + R882H) compared to wild-type genotype (R882C + R882H) compared to wild-type genotype Decreased global DNA methylation in subjects with DNMT3B rs2424909 GG genotype ($P = 0.031$)	GSTT1 null is related to a reduced S- PMA excretion ($P = 0.041$), compared to GSTT1 no null	GSTT1 null is related to a reduced S- PMA excretion (P < 0.0001), compared to GSTT1 no null	G5TT1 null is related to a reduced S- PMA excretion (<i>P</i> = 0.0098) compared to G5TT1 no null G5TM1 null did not influence biomarker excretion
Genes and polymorphisms studied		DNMT3A rs36012910 rs1550117 R882 DNMT3B rs1569686 rs2424909 rs2424913	GSTT1 Null and no null GSTM1 Null and no null GSTP1 rs1695	CYP2E1 rs2031920 rs6413432 NQO1 rs1800566 GSTT null and no null MPO rs 2 333 227 (not analyzed)	GSTT1 null and no null GSTM1 null and no null
Evaluated variable*		MN and methylation	Urinary biomarkers: S- PMA, PH and t,t-MA	Urinary biomarkers: S- PMA, PH and t,t-MA	Urinary biomarkers: S- PMA and t,t-MA
Mean benzene exposure		6.4 mg/m³	Groups: High benzene exposure (1 ppm: n = 33) 15 ± 19 ppm Low benzene exposure (<1 ppm: n = 37) 0.20 ± 0.22 ppm	Groups: GSTT1 null: 7.5 \pm 9.1 ppm no null: 11.7 \pm 20.6 ppm NQO1 rs1800566 Wild-type variant: 12.1 \pm 23.6 ppm Homozygous variant:8.4 \pm 11.8 ppm Heterozygous variant:10.3 \pm 11.8 ppm	34.5 µg/m³
Participants (age range or mean [in years], gender)		236 male 276 female	33-57 y.o. all males		33.3-50.3 yo All males
Sample size		410 benzene-exposed shoe factory workers102 control participants	105 exposed workers from Taiwan	130 exposed workers 51 unexposed workers	28 petrochemical workers from Italy
Country		China	Taiwan	China	Italy
Authors and year of publication		Zhang et al ⁴⁶	Lin et al ⁴⁷	Qu et al ⁴⁸	Carrieri et al ⁴⁹

/ ment				
Quality assessment score	7/9	5/9	8/9	5-PMA, S- lation.
Results	Higher MN frequency in subjects with: CYP2E1 rs3813867 mutant allele (CC + GC) [FR = 1.15 (95% CI 1.02-1.29), $P = 0.02$] and rs2031920 variant allele (CT + TT) [FR = 1.23 (95% CI 1.09-1.37), P < 0.01] both SNPs compared with the wild type Higher MN frequency (adjusted for age, gender and cumulative exposure dose) in subjects with rs2031920 variant allele (CT + TT) [FR = 1.17 (95% CI 1.04-1.31), P < 0.01], compared to the wild type	Increased risk of CBP in exposed workers with 65771 null [OR = 4.45 (95% CI 1.13-17.54)] • NQO1 rs1800566 plus G5771 null at the same time [OR = 1.14 (95% CI 0.42-305)]	GSTT1 no null significantly increases the urinary levels of S-PMA (P < 0.0094), compared to GSTT1 null GSTM1 null and no null showed no effect on biomarker excretion	Abbreviations: CA, chromosomal aberrations; CAT, catechol; CBP, chronic benzene poisoning; FR, frequency ratio; HQ, hydroquinone; MN, micronucleus; OR, odds ratio; ORadj. adjusted odds ratio; PH, phenol; RR, risk ratio; S-PMA, S- phenylmercapturic acid; t.t-MA, <i>trans</i> -muconic acid; WBC, white blood cell; y.o., years old. "The evaluated variables were changed in risk of developing chronic benzene poisoning, excretion of urinary biomarkers, blood cell count or hematotoxicity; the presence of micronucleus, chromosomal aberrations, and methylation.
Genes and polymorphisms studied	GSTM1 null and no null GSTT1 null and no null GSTP1 rs1695 CYP2E1 rs2031920 rs6413432 mEH exon 3 rs1051740 mEH exon 4 rs2234922	GSTM1 Null and no null GSTT1 Null and no null NQ01 rs1800566 CYP2E1 rs3813867	GSTT 1 Null and no null GSTM 1 Null and no null	micronucleus; OR, odds ratio; ORadj, adju r hematotoxicity; the presence of micronu
Evaluated variable*	Σ	Risk of developing CBP	Urinary biomarkers: S- PMA, urinary benzene and t,t- MA	o; HQ, hydroquinone; MN, narkers, blood cell count o
Mean benzene exposure	6.4 mg/m³	1	32.6 ± 50.6 (µg/m ³) for exposed workers 11.5 ± 3.2 (µg/m ³) for controls	re poisoning; FR, frequency rati y.o., years old. soning, excretion of urinary bion
Participants (age range or mean [in years], gender)	293 female 293 female	46 male 74 female	All males 20-72 y.o.	BP, chronic benzer ; white blood cell; ronic benzene poi
Sample size	Cases: 385 benzene-exposed workers Controls: 197 non-exposed workers	120 workers	146 workers employed at an oil refinery25 non-exposed participants as a control group	Abbreviations: CA, chromosomal aberrations; CAT, catechol; CBP, chronic benzene poisoning; F phenylmercapturic acid; t,t-MA, <i>trans,trans</i> -muconic acid; WBC, white blood cell; y.o., years old. *The evaluated variables were changed in risk of developing chronic benzene poisoning, excreti
Country	China	China	Italy	A, chromoso 'ic acid; t,t-N 'ariables wer'
Authors and year of publication	Zhang et al 2014	Wan et al ⁵⁰	Carrieri et al ⁵ 1	Abbreviations: C phenylmercaptui *The evaluated v

TABLE 1 (Continued)

16 of 26 WILEY_Health Science Reports

TABLE 2 Effect of different polymorphisms on the development of CBP

	fect of different polymorphisms on the development of CBP			
Group/gene	Genes and polymorphisms	Effect on CBP	Risk	References
NQO	NQO1 rs1800566 rs1800566 (T/T genotype) rs1800566 (combined with null GSTT1)	Possible ^a	No change Increased Increased	38 39 50
MPO	MPO rs7208693 rs2333227	No ^b	No change No change	38 39
СҮР	CYP1A1 rs4646421 rs4646422 rs1048943 rs4646903 rs4646903 (T/T genotype)	Conflicting ^c	No change No change No change No change Increased	38 38 38 38 38 32
	CYP1A2 rs2445618 rs762551 rs2472304 rs2470890	No ^b	No change No change No change No change	38 38 38 38
	CYP2D6 rs1065852 (C/C + C/T genotype) rs1135840 (C/C genotype)	Yes ^d	Increased Increased	32 32
	CYP1B1 rs1056836	No ^b	No change	38
	CYP2E1 rs2031920	No ^b	No change	39
GST	GSTT1 non-null null GSTM1	Yes ^d Conflicting ^c	No change Increased	39,50 39,50 39
	null (in combination with NQO1 rs1800566 variation [T/T], GSTT1 null) null and non-null	g	No change	50
	GSTP1 rs1695 (AA genotype, non-alcohol drinkers)	Yes ^d	Increased	38
XRCC	XRCC1 rs25487 (AA genotype) rs1799782 (TT genotype) rs25489 (Arg/His+His/His genotype combination) rs1799782(Arg/Trp + Trp/Trp genotype combination)	Yes ^d	Increased Increased Increased Decreased	35 35 34 34
	XRCC2 ^{**} rs3218536	-	-	34
	XRCC3 rs861539	No ^b	No change	34
ERCC	ERCC1 rs11615 rs3212986	Yes ^d	Increased No change	27 27 27 27
	ERCC2 rs13181 rs1799793	No ^b	No change No change	27 35
	ERCC3 rs4150441 (GA and GA $+$ AA genotypes)	Yes ^d	Increased	

TABLE 2 (Continued)

Group/gene	Genes and polymorphisms	Effect on CBP	Risk	References
CDKN2A	CDKN2A rs3731245 (GA + AA genotypes in combination with MDM2 rs3730485 WW)	Yes ^d	Decreased	11
CDKN1A	CDKN1A rs1801270 (CA + AA genotype) rs1059234 (CT + TT genotypes)	Yes ^d	Decreased Decreased	28 28
POLR1G [*]	POLR1G rs967591 (GA and GA + AA genotypes)	Yes ^d	Decreased	35
PPP1R13L [*]	PPP1R13L rs1005165 (T genotype)	Yes ^d	Decreased	35
hMTH	hMTH rs4866	Yes ^d	Increased	33
OGG1	OGG1 rs1052133	Yes ^d	Increased	33
MUTYH	MUTYH rs3219489	No ^b	No change	33
TP53	TP53	No ^b	No change	28
	rs17878362	No ^b	No change	28
	rs1042522 rs1625895	No ^b	No change	28
UGT	UGT1A6 rs2070959	No ^b	No change	32
	UGT1A7 rs11692021	No ^b	No change	32
SULT1A1	SULT1A1 rs9282861	No ^b	No change	32
ADH1B	ADH1B rs1229984	No ^b	No change	38
EPH	EPHX1 rs3738047 (GA + AA genotypes) rs2854451 rs2234922 rs1051741	Yes ^d	Increased No change No change No change	38 38 38 38
	EPHX2 rs781141	No ^b	No change	38
UGT1A6	UGT1A6 rs6786892 rs1105879 rs4124874 rs3755319 rs887829 rs4148323	No ^b	No change No change No change No change No change No change	38 38 38 38 38 38
GADD45A	GADD45A rs581000 rs532446 rs11544978	Yes ^d	Decreased Decreased No change	11 11 11
MDM2	MDM2 rs3730485 (in combination with CDKN2A rs3731245) rs2279744	Yes ^d	Decreased No change	11 11
APE1	APE1 rs1130409	No ^b	No change	34
ADPRT	ADPRT rs1136410	No ^b	No change	34
ХРВ	XPB rs4150441 (GA and GA + AA genotypes)	Yes ^d	Increase	35

TABLE 2 (Continued)

Group/gene	Genes and polymorphisms	Effect on CBP	Risk	References
ХРС	XPC rs2279017 rs2228001	No ^b	No change No change	35 35
XPF	XPF rs4781560	No ^b	No change	35

^aPossible: More than half of all the studies that researched that polymorphism has encountered a relationship between it and the development of CBP. ^bNo: None of the studies that researched the polymorphism encountered a relationship between it and CBP.

^cConflicting: Half of the studies that researched said polymorphism found a relationship between it and CBP, yet the other half did not.

^dYes: All of the studies that researched the polymorphism found a relationship between it and a higher risk of developing CBP.

*This effect was exclusively observed in males.

**The study did not detect any subjects with the desired allele.

3.2.1 | NQO1 and MPO

Three publications evaluated the difference in susceptibility of developing CBP among patients with polymorphisms in the NQO1 and MPO genes; however, none of these studies found any relationship between the latter gene and the outcome.^{38,39,50} Conversely, only one article found no association between NQO1 polymorphisms and the risk of developing CBP,³⁸ while the other two found to some degree a greater risk of benzene poisoning on individuals with a NQO1 polymorphism. Chen et al found that the NQO1 rs1800566 TT homozygous genotype was associated with an increased risk of CBP [OR = 2.82 (95% CI 1.42-5.58)].³⁹ Wan et al found that the increase in the risk of CBP was only significant when the NQO1 rs1800566 genotype was present simultaneously as the null GSTT1 gene [OR = 1.14 (95% CI 0.42-3.05)].⁵⁰

3.2.2 | Cytochrome P450 encoding polymorphisms

There were three articles that studied the different CYP gene polymorphisms. Two of them researched CYP1A1, one of which found no relation between the polymorphisms and the risk of CBP,³⁸ while the other found that the exposed workers with polymorphisms in CYP1A1 rs4646903 are at a greater risk of CBP [ORadj = 1.21 (95% CI 1.03-1.42)].³² Gu et al also discovered that people with CYP2D6 polymorphisms are more susceptible to CBP: [ORadj = 2.11 (95% CI 1.22-3.65)] for rs1065852 (CC + CT genotype) and [ORadj = 1.69 (95% CI 1.04-2.74)] for rs1135840 (CC genotype).³² Nevertheless, none of the articles found any correlation between the possibility of developing CBP and the CYP1A2, CYP1B1, and CYP2E1 polymorphisms.^{32,38,39}

3.2.3 | GSTT1 and GSTM1

Three studies examined this correlation. Mitri et al found a relationship between the *GSTM1* null genotype and a higher risk of developing CBP [OR = 5.13 (95% CI 1.13-23.15)]³⁶ while Chen et al only found it when said polymorphism was combined with the *NQO1* rs1800566 TT homozygous genotype and the *GSTT1* null [OR = 16.13 (95% CI 3.15-83.33)].³⁹ Two of the papers found that the *GSTT1* null genotype was related to a higher CBP risk with an [ORadj = 1.91 (95% CI 1.05-3.45)] for Chen et al and an [OR = 4.45 (95% CI 1.13-17.54)] for Wan et al.^{39,50}

3.2.4 | XRCC1, XRCC2, and XRCC3

Two papers studied this relationship; however, *XRCC2* could not be evaluated because the selected variant genotype was not detected. Additionally, they did not find any correlation between the *XRCC3* rs861539 variant and variation in CBP risk.^{34,35} Regarding *XRCC1*, Zhang et al detected that individuals carrying *XRCC1* rs1799782 and rs25489 alleles had a decreased [ORadj = 0.60 (95% CI 0.37-0.98)] and an increased [ORadj = 1.67 (95% CI 1.02-2.74)] risk of CBP, respectively.³⁴ According to Xue et al, the workers who had the *XRCC1* rs25487 AA [ORadj = 14.898 (95% CI 6.55-30.21)] and the rs1799782 TT genotypes also had an increased risk of developing CBP; it is important to mention that the increased risk with rs1799782 was exclusive to male [OR = 9.33 (95% CI 1.59-54.67)], alcohol drinkers [OR = 8.0 (95% CI 1.32-48.65), with an exposure lesser than 12 years [OR = 2.61 (95% CI 1.05-6.51)].³⁵

3.2.5 | ERCC1 and ERCC2

One of the studies evaluated the effect of *ERCC1* and *ERCC2* and did not find any association between the latter gene and the risk of CBP; nonetheless, it found that individuals carrying the *ERCC1* rs11615 TT genotype had an increased risk of benzene poisoning, compared to those carrying the CC genotype [OR = 3.21 (95% CI 1.36-7.60), P = 0.006].²⁷

3.2.6 | Other genes

More information about other genes can be found in Table 2.^{11,28,32-35,38}

3.3 | Susceptibility to hematotoxicity and changes in blood cell count

Polymorphisms on certain genes could increase susceptibility to hematotoxicity, which could be reflected with an altered blood cell count.⁸ We found eight studies that researched this correlation (Table 3).

TABLE 3 Effect of different polymorphisms on the development of hematological changes

Gene/Group	Polymorphisms and/or genotypes	Hematological effect	Effects on blood cell count	References
NQO1	rs1800566	No ^a	_	29
MPO	rs2071409	Yes ^b	Decreased WBC count	1
CYP2E1	rs2031920 CT genotype	Yes ^b	Decreased WBC count	7
	rs3813867	Conflicting ^c	Decreased WBC count	6,7
	rs2031920 and rs6413432	No ^a	-	29
GST	GSTP1 rs1695	No ^a		7
	GSTM1 Null genotype	Conflicting ^c	Decreased WBC count	6,7
	GSTT1 Null genotype	Conflicting ^c	Decreased WBC count	6,7
IL-1A	rs1800587	Yes ^b	Decreased WBC count	9
IL-4	rs22432484	Yes ^b	Decreased WBC count	9
IL-10	rs1800871	Yes ^b	Decreased WBC count	9,41
IL-12A	rs568408	Yes ^b	Decreased WBC count	9
VCAM1	rs1041163	Yes ^b	Decreased WBC count and CFU-GEMM	9
	rs3176867	Yes ^b	Decreased WBC count	1
CSF3	rs1042658	Yes ^b	Augmented CFU-GEMM and WBC count	9
ALOX5	rs7099684	Yes ^b	Decreased WBC count	1
WRN	rs4987236	Yes ^b	Decreased WBC count	40
	rs2725349	Yes ^b		
	rs1800392	Yes ^b		
	rs2725362	Yes ^b		40,41
	rs2230009	Yes ^b		41
TP53	rs1042522	Yes ^b	Decreased WBC count	40,41
	rs12951053	Yes ^b		41
BRCA2	rs1801406	Yes ^b	Decreased WBC count	40
BLM	rs2270132	Yes ^b	Decreased WBC count	41
	rs414634	Yes ^b		
	rs16944894	Yes ^b		
RAD51	rs4924496	Yes ^b	Decreased WBC count	41
WRAP53	rs2287499	Yes ^b	Decreased WBC count	41
ERCC3	rs4150441	Yes ^b	Increased WBC count	26
	rs6731176	Yes ^b		
VEGF	rs3025030 rs833058	Yes ^b	Increased WBC count	26

^aNo: None of the studies investigated that the polymorphism encountered a relationship between it and hematological changes.

^bYes: All of the studies investigated that the polymorphism encountered a relationship between it and hematological changes.

^cConflicting: Half of the studies researched said that polymorphism found a relationship between it and CBP, yet the other half did not.

3.3.1 | NQO1 and MPO

Two papers researched these two genes. One of them demonstrated that the *MPO* rs2071409 polymorphism decreases the white blood cell (WBC) count in exposed subjects, and possibly affects WBC sub-types (P < 0.001).¹ *NQO1* rs1800566 polymorphism was studied by Pesatori et al, and they found no association between this SNP and blood cell count.²⁹

3.3.2 | CYP2E1

There were three studies that reported about *CYP2E1*. A research carried out by Ye et al found that WBC count was lower for individuals who possessed the CT genotype of the *CYP2E1* rs2031920 polymorphism compared to the CC genotype (P = 0.02). The GC genotype of the *CYP2E1* rs3813867 polymorphism was associated with a significantly lower WBC count when compared to the GG genotype

(P = 0.02).⁷ rs3813867 polymorphism was also researched by Nourozi et al; however, they did not find a statistically significant relationship between this *CYP2E1* SNP and altered blood analysis values.⁶ Both *CYP2E1* rs2031920 and rs6413432 polymorphisms were evaluated by Pesatori et al, again no significant relationship was found between those SNPs and blood cell count.²⁹

3.3.3 | GST enzymes (GSTT1, GSTM1, and GSTP1)

Two of the papers analyzed all three enzymes,^{6,7} evaluating the *GSTM1* null genotype, *GSTP1* rs1695 polymorphism, and *GSTT1* null genotype. None of them found a correlation between the *GSTP1* polymorphism and anomalous hematological indices. However, regarding *GSTM1* and *GSTT1*, the results disagreed: one of the studies found that WBC count in *GSTT1* null (P = 0.045) and *GSTM1* null (P = 0.03) genotypes decreased compared to the *GSTT1/GSTM1* present group,⁷ while the other study found that individuals with *GSTM1* null genotype had a significantly higher mean value of leukocytes (P = 0.026), and subjects with *GSTT1* null genotype presented a lower platelet count (P = 0.015). Nonetheless, this same study observed that subjects with *GSTT1* null genotype had a higher risk for hematological disorders compared to those with positive genotype [OR = 2.1 (95% CI 1.23-3.56)].⁶

3.3.4 | Other genes

More information about other genes can be found in Table 3.^{1,9,26,40,41}

3.4 | Effect on urinary biomarker

Eleven studies researched the influence that several polymorphisms have on the production of different urinary excreted metabolites produced in the metabolism of benzene, commonly used as biomarkers of exposure.

3.4.1 | GST enzymes (GSTT1, GSTM1, and GSTP1)

Ten studies analyzed the relationship between the polymorphisms of GST enzymes and the urinary excretion of benzene metabolites. Four of them studied both the enzyme's *GSTM1* null and no null genotypes, and they found no correlation between the genotypes and the biomarkers of benzene exposure.^{30,47,49,51} Conversely, four other studies found a significant correlation: both Mansi et al and Manini et al found that an expression of the *GSTM1* null polymorphism was involved in a lower urinary excretion of S-PMA (P < 0.001 and P = 0.010 respectively); furthermore, Carbonari et al (P < 0.05) and Kim et al (P = 0.018) discovered similar results.^{3-5,45} Eight studies established an inverse relationship between the *GSTT1* null polymorphism and the quantity of the S-PMA marker excreted, both in smokers and non-smokers (P values on Table 1).^{3-5,45,47-49,51} Also, according to

Chanvaivit et al and these eight studies, there was no association between *GSTT1* null and the t,t-MA metabolite.^{3-5,31,45,47-49,51} Three studies screened the influence of the *GSTP1* polymorphism on urinary biomarkers; however, none found any interaction between these two factors.^{3,4,47}

3.4.2 | CYP2E1

Six papers studied the effect of this polymorphism; four of them did not find any correlation.^{30,31,45,48} The other two found conflicting results: Kim et al concluded that the workers with an homozygous variant genotype for the *CYP2E1* rs2031920 SNP, produced significantly lower levels of t,t-MA (P < 0.001), phenol (PH) (P < 0.001), and hydroquinone (HQ) (P < 0.001) than workers who had the wild-type variant allele.³ Fustinoni et al found a higher t,t-MA and a lower U-benzene on subjects with at least one variant allele in *CYP2E1* rs6413432 (P = 0.03) and rs2031920 (P < 0.01), respectively.²

3.4.3 | NQO1

Two out of four studies researched the influence of the NQO1 rs1800566 polymorphism and the biomarkers excretion that did not find any significant relationship between these two variants.^{31,48} Instead, one found that patients with at least one variant allele of NQO1 rs1800566 affected five metabolites: t,t-MA, S-PMA (P = 0.001), PH (P = 0.022), catechol (CAT) (P = 0.036) and HQ (P = 0.036), as they found lower levels of them in these participants.³ The other study found that the NQO1 rs1800566 wild-type polymorphism decreased the t,t-MA/S-PMA fraction in non-smokers (P = 0.04).⁴⁵

3.5 | Micronucleus and CAs

Four studies reported the existing relationship between polymorphisms on certain genes and the expression of cytokinesis-block micronucleus (MN) and/or the frequency of CA in benzene-exposed workers and non-exposed controls.

3.5.1 | NQO1 and MPO

Two papers studied either or both of these enzymes.^{42,43} One of them showed that exposed workers with NQO1 rs1800566 polymorphism (TT genotype) had significant increases in MN [RR = 1.9 (95% CI 1.5-2.3)] and CA [RR = 2.6 (95% CI 1.7-3.9)] frequencies when compared to controls with CC and CT genotypes; moreover, it suggested that the benzene-exposed population with the *MPO* rs2333227 polymorphism (GG wild-type genotype) had a significant rise in CA frequency [RR = 2.3 (95% CI 1.3-4.0)] compared to non-

exposed population with GA or AA genotypes.⁴² In contrast, the other paper evidenced that mutated homozygous genotype of NQO1 rs1800566 polymorphism (TT genotype) was related with lower MN frequencies [FR = 0.79 (95% CI 0.66-0.95)] when compared to the homozygous wild-type genotype (CC genotype).⁴³

3.5.2 **DNA** repair genes

One study analyzed the relationship between polymorphisms on genes involved in the DNA repairing process and the frequency of MN.⁴⁴ Both the base excision (XRCC1 and APE1) and nucleotide excision repair pathway genes (XPA, XPC, XPG, ERCC1, and ERCC2) were studied. They found that MN frequencies were higher in XRCC1 rs25487 GA [FR = 1.20 (95% CI 1.06-1.37), P = 0.006] and AA [FR = 1.50 (95% CI 1.16-1.90), P = 0.002] alleles, APE1 rs1130409 GT [FR = 1.20 (95% CI 1.04-1.37), P = 0.012] and GG [FR = 1.28 (95% CI 1.05-1.55), P = 0.01], XPG rs17655 GC [FR = 1.18 (95% CI 1.02-1.38), P = 0.038] and ERCC1 rs3212986 TT [FR = 1.55 (95% CI 1.31-1.83), P < 0.001] with a directly proportional relationship between the number of present mutant alleles of these polymorphisms and MN frequency.⁴⁴ Kim et al also studied XRCC1 rs25487 polymorphism, finding that, among exposed workers, subjects with AA variant type displayed a significantly higher CA frequency compared to its wild-type controls [RR = 2.2 (95% CI 1.5-3.1)].42

3.5.3 CYP2E1

One case-control study carried out by Zhang et al, showed significantly increased MN frequency for carriers of CYP2E1 rs3813867 (CC + GC genotypes) [FR = 1.15 (95% CI 1.02-1.29), P = 0.02] and rs2031920 (CT + TT genotypes) [FR = 1.23 (95% CI 1.09-1.37), P < 0.01]; while the opposite was found with the CYP2E1 rs6413432 polymorphism.⁵² Another paper also studied the relationship between rs3813867 polymorphism and MN expression in benzene-exposed workers without a statistically significant increase in MN frequencies for individuals carrying this SNP.43

3.6 Methylation

Two of the reviewed studies explored the association between genetic polymorphisms and DNA methylation, and whether this methylation was related to benzene exposure. One of them genotyped four commonly studied SNPs on three metabolic enzymes: CYP1A1 (rs4646903), EPHX1 (rs1051740 and rs2234922), and NQO1 (rs1800566); they also analyzed DNA methylation on 11 genes associated with benzene-induced hematotoxicity (BLM, CY1A1, EPHX1, ERCC3, NQO1, NUDT1, p15, p16, RAD51, TP53, and WRAP53). The authors found that ERCC3 methylation was higher on exposed individuals. Furthermore, they established that a larger number of C alleles

on EPHX1 rs1051740 polymorphism was related to a reduction of ERCC3 methylation (P = 0.001), concluding that this SNP may be protective against benzene-induced hypermethylation.³⁷ On the contrary, Zhang et al demonstrated that benzene-exposed workers experienced significant global DNA hypomethylation compared to non-exposed subjects. As factors that influenced this process, DNMT3A (R882) variant allele (R882C + R882H) (P = 0.094) and DNMT3B rs2424909 polymorphism (GG genotype) (P = 0.031) showed an association with decreased global DNA methylation.⁴⁶

Results adjustment to smoking status 3.7

thirty-one out of 36 included studies incorporated in their analysis a multivariate adjustment for the population that smoked, some demonstrating worse outcomes for smokers compared to nonsmokers.^{1-7,9,11,26-29,33-35,37-46,48-52} For instance, seven papers found that smoking was an important confounder for benzene biomarkers, as smokers excreted higher concentrations of benzene metabolites than non-smokers.^{2-5,45,49,51} In five studies, the health outcomes of benzene exposure were only statistically significant when they stratified the population in smokers and non-smokers.^{11,27,29,33,34} Moreover, two articles found evidence that smoking affects the prognosis of benzene poisoning and lowers the WBC count in exposed workers.^{7,50} On the other hand, six papers did not find a statistically significant association between the smoking habit and the researched health outcome.^{28,35,38,43,44,52} Furthermore, in two out of five studies that did not adjust for smoking habits, all of the participants were non-smokers.31,47

DISCUSSION 4

In this review, we aimed to evaluate the existent relationship between genetic polymorphisms and the risk of developing adverse health effects in benzene-exposed workers. Among the assessed studies, we encountered that the most researched outcomes of benzene exposure were the development of CBP, the increase or decrease on the excretion of urinary biomarkers and hematotoxic effects. The genes that showed some consistent associations in the effects of their polymorphisms in the human body were NQO1, GSTT1, GSTM1, XRCC1, MPO, and CYP2E1.

NQO1 is a key enzyme involved in benzene metabolism because it reduces benzoquinones to HQ and CAT, resulting in the detoxification of those metabolites. It has been theorized that polymorphisms that cause a decrease in this enzyme's activity probably increase the risk of bone marrow toxicity and other adverse effects.53 In this review, regarding the polymorphisms on the NQO1 encoding gene, we found that they have a significant effect on the risk of developing CBP,^{39,50} on MN frequencies⁴² and urinary biomarker excretion,^{3,45} further validating this hypothesis. Two of the evaluated studies found an increased frequency of CBP in individuals with NQO1 rs1800566.39,50 Those results are consistent with a modification in

NQO1's detoxifying properties; thus, making the individual's organism more permissive to long-term toxic effects.

On the other hand, only one study found no relationship between CBP and NQO1 polymorphisms, but it also stated that the sample of exposed workers with the studied polymorphism was probably not big enough to establish a statistically significant relationship in this variable.³⁸ According to Pesatori et al, changes in the expression of NQO1 in combination with a MPO polymorphism did not show a correlation with altered WBC count²⁹; however, this study did not have enough study subjects to be statistically significant; making it clear that more papers are necessary to reinforce these results.

Regarding biomarkers of exposure, theoretically, if you pare NQO1 activity, fewer benzoquinones will be reduced, subsequently producing less urinary biomarkers. Two studies found that the patients who had the variant NQO1 rs1800566 (C \rightarrow T) polymorphism (which decreases NQO1's activity) showed a lower excretion of biomarkers, which produced a lower t,t-MA/S-PMA fraction.^{3,45} Conversely, Chanvaivit et al and Qu et al did not find any significant change.^{31,48} This discrepancy is likely caused by the median level of benzene exposure, which was lower in the subjects of the studies that did not find any correlation between NQO1 polymorphisms and the excretion of urinary biomarkers, compared to the ones that did.

Both Kim et al and Fang et al studied NQO1 rs1800566 involvement in MN frequency and CA; however, their results were contradictory.^{42,43} This disagreement can be explained by the difference in the population size, as it was bigger in Fang et al's study, which established that the NQO1 CC genotype had a higher MN frequency than the TT genotype.⁴³ Nonetheless, there are few studies that explore this subject and research with a bigger population sample is needed to understand this phenomenon better.

Considering that GSTs help in the benzene oxide (BO) detoxification process and, by extension, reduce the carcinogenic potential of benzene,⁵⁴ the two most studied enzymes of this family within the papers that we reviewed were GSTT1 and GSTM1. All of them considered the null and no null genotypes of these genes as modifying factors of biomarker excretion, CBP, and hematological changes. Regarding urinary biomarker excretion, almost all of the analyzed papers concluded that GSTT1 null genotype was related to lower excretion of S-PMA, 3-5,45,47-49,51 while the results were very conflicting for GSTM1 null genotype, with four of the articles finding no correlation between this genotype and S-PMA excretion.^{30,47,49,51} However, this is consistent with in vitro studies, which have identified that GSTT1 is more important in the BO detoxification process than GSTM1 because the latter is affected by competing non-enzymatic product formation and lower enzymatic activity.54

Regarding CBP, the importance of *GSTT1* was once again demonstrated as a toxicity-protector enzyme. Two studies associated the *GSTT1* null genotype to an increased risk of benzene poisoning^{39,50}; moreover, it was found that *GSTM1* null genotype has a strong relationship with CBP.³⁶ The effects of GST enzymes on hematological abnormalities are related to their protective function against benzene, with the reviewed papers showing that *GSTT1* null genotype is correlated with lower WBC and platelet count.^{6,7} It has been recently reported that GST appears to defend against benzene-induced DNA damage; therefore, with the loss of GSTT1 its DNA-defensive characteristic is also gone.⁷

CYP2E1 is a phase I enzyme, which plays a key role on the metabolic pathway of benzene, given that it is responsible for the first step of benzene breakdown, producing BO and then intermediate metabolites, which accumulate in the bone marrow and undergo autoxidation or activation by peroxidases to yield the corresponding quinones, which are believed to be among the ultimate toxic metabolites of benzene.⁷ Consequently, some of the articles we reviewed determined a relationship between *CYP2E1* polymorphisms and effects on hematological abnormalities, the rs2031920 and rs3813867 were two *CYP2E1* of the polymorphisms that showed a statistically significant association with an altered WBC count.⁷

As for biomarker excretion, two studies reported a relationship between some of the *CYP2E1* polymorphisms and different biomarkers levels.^{2,3} In accordance with the *CYP2E1* function on benzene metabolism, one study showed that the rs2031920 polymorphism was related to lower levels of t,t-MA, PH, and HQ.³ Another study demonstrated a relationship between rs2031920 and rs6413432 variant allele polymorphisms with lower U-benzene and higher t,t-MA, respectively.² Nonetheless, four of the reviewed works did not find a correspondence between *CYP2E1* polymorphisms and biomarker excretion changes.^{30,31,45,48} This lack of consistency with the results among papers may be a consequence of the diversity of populations in the studies, as the family of cytochrome P450 (CYP450) enzymes might present several SNPs on different ethnical groups, which determines the toxicity of and response to a number of substrates, benzene included.⁵⁵

Another relevant enzyme is MPO, which converts CAT, HQ and 1,2,4-benzenetriol to highly reactive intermediates: 1,2-benzoquinone, 1,4-benzoquinone, and 1,2,4-benzoquinone.⁵⁶ Few studies correlated the MPO encoding gene polymorphisms and human physiological changes, and only one of them found statistically relevant results regarding the rs2071409 polymorphism and hematological changes.¹ Another one suggested that the rs2333227 polymorphism had a significant rise in CA frequency, compared to the non-exposed population with the GA or AA genotype.⁴² All of this can be explained by CAT's increased toxic effect in progenitor cells, which is caused by a decreased MPO metabolic activity.^{57,58}

Though not directly involved in the benzene metabolic pathway, the polymorphisms in *XRCC1* have shown consistent relationship with worsening adverse effects secondary to benzene exposition. Specifically, the rs25487 polymorphism was found to be associated with higher MN and CA frequencies,^{42,44} which are indicators of the extent of chromosomal damage in human populations exposed to genotoxic agents, such as benzene, and some studies have found a link between chromosomal damage and an increased cancer risk.⁴² Furthermore, rs25487, rs1799782, and rs25489 polymorphisms were found to have an increased risk of developing CBP.^{34,35} *XRCC1* plays an important role in single-strand break repair and base-excision repair, acting as a scaffolding protein for other repair factors, including DNA ligase IIIα,

DNA polymerase β or APE1.⁵⁹ If this repairing function was impaired (which happens with the aforementioned polymorphisms), DNA lesions would accumulate; thus, configuring a threat to genetic stability and cell survival, accelerating mutation rates and increasing CA levels.

Concerning the relationship of the smoking habit and benzene health effects, several authors have found that it is an important source of environmental benzene contamination, and it is directly related to some adverse health outcomes.^{60,61} In this review, most studies predicted that smoking was a confounding factor and therefore adjusted their analysis to have more reliable results. For instance, some of the reviewed papers found that the smoking habit correlates with worse health outcomes and suggested that future research should take into account this factor while studying occupational exposure.^{2-5,7,27-29,33,34,45,49-51} Conversely, a minority of the included articles did not find a statistically significant interaction between those two variables; however, these results may be caused by the scarce quantity of smokers compared to non-smokers both in the group with exposed workers and the controls in most of these studies.^{28,35,38,43,44,52}

These statistically relevant outcomes have established the link between genetic polymorphisms and the risk of developing adverse health effects in benzene-exposed workers with a different genetic background. These findings should enable occupational medicine specialists, local governments and policy makers to create and improve new evidence-based guidelines for benzene exposure limits that take into account the genetic diversity of the workforce. Those improved regulations will help workers to avoid health risks, thus lowering public health costs and overall making the population healthier while providing insight for future research.

4.1 | Strengths and limitations

By using the PRISMA guidelines and the Newcastle-Ottawa quality assessment score, this review captures a significant number of studies, anticipating and working around bias; nevertheless, weak selection bias could be induced by limiting the language of the included studies to English and Spanish. In addition, publishing bias should not be ignored, because papers that found a correlation between polymorphisms and different benzene-exposure outcomes are more likely to be published than those with no significant findings. Additionally, some papers used the same study population, which can lead to more bias. Moreover, some polymorphisms did not have the same quantity of evidence as others, which may affect the results.

5 | CONCLUSION

Overall, this review highlights the detrimental effects of occupational exposure to benzene. It also establishes a clear relationship between some polymorphisms and the extent of the consequences that come with the occupational exposure to this toxicant. While there are several studies investigating this topic, there are not enough papers to establish a consensus with statistically relevant results regarding some of the polymorphisms. Future research should focus on gathering broader cohorts with the desired polymorphism, given that the expression of genetic variants was not present in all of the participants, even when the cohort had a higher population. In conclusion, benzene is an important threat to occupational health worldwide; therefore, regulations should be adjusted to protect all the exposed workers, especially those with high-risk genetic variants.

ACKNOWLEDGEMENTS

We would like to thank Professor Claudia Ortiz at Universidad de Santander for her valuable help to the development of this paper, especially as a source for resolving genetics-related questions that surged in the conceptualization and analysis of the review. We would also like to thank Mr. Cameron Hahn for revising the grammar of the manuscript.

FUNDING

Publication costs were supported by Ministerio de Ciencia, Tecnología e Innovación (Grant number: COL126780763345, contract RC.847-2019). However, the funding source did not have any involvement in the study design; collection, analysis, and interpretation of data; writing of the report or the decision to submit the report for publication.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

Conceptualization: Verónica Ramírez-Lopera, Daniel Uribe-Castro, Tania Liseth Pérez-Cala

Formal Analysis: Verónica Ramírez-Lopera, Daniel Uribe-Castro, Tania Liseth Pérez-Cala, Henry Bautista-Amorocho, Jorge Alexander Silva-Sayago, Enrique Mateus-Sánchez, Wilman Yesid Ardila-Barbosa

Funding Acquisition: Tania Liseth Pérez-Cala and Henry Bautista-Amorocho

Investigation: Verónica Ramírez-Lopera, Daniel Uribe-Castro, Tania Liseth Pérez-Cala

Methodology: Verónica Ramírez-Lopera, Daniel Uribe-Castro, Tania Liseth Pérez-Cala

Project Administration: Verónica Ramírez-Lopera, Jorge Alexander Silva-Sayago

Supervision: Enrique Mateus-Sánchez, Wilman Yesid Ardila-Barbosa, Tania Liseth Pérez-Cala

Validation: Henry Bautista-Amorocho, Jorge Alexander Silva-Sayago, Enrique Mateus-Sánchez, Wilman Yesid Ardila-Barbosa

Writing – Original Draft Preparation: Verónica Ramírez-Lopera, Daniel Uribe-Castro

Writing – Review & Editing: Verónica Ramírez-Lopera, Daniel Uribe-Castro, Tania Liseth Pérez-Cala, Henry Bautista-Amorocho, Jorge Alexander Silva-Sayago, Enrique Mateus-Sánchez, Wilman Yesid Ardila-Barbosa

All authors have read and approved the final version of the manuscript.

Verónica Ramírez-Lopera had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.

TRANSPARENCY STATEMENT

The corresponding author confirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Verónica Ramírez-Lopera ^(b) https://orcid.org/0000-0002-3609-8025 Daniel Uribe-Castro ^(b) https://orcid.org/0000-0002-9222-5703 Jorge Alexander Silva-Sayago ^(b) https://orcid.org/0000-0001-8147-6374

Tania Liseth Pérez-Cala D https://orcid.org/0000-0001-5095-3289

REFERENCES

- Shen M, Zhang L, Lee KM, et al. Polymorphisms in genes involved in innate immunity and susceptibility to benzene-induced hematotoxicity. *Exp Mol Med.* 2011;43(6):374-378.
- Fustinoni S, Consonni D, Campo L, et al. Monitoring low benzene exposure: comparative evaluation of urinary biomarkers, influence of cigarette smoking, and genetic polymorphisms. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.* 2005;14(9):2237-2244.
- Kim S, Lan Q, Waidyanatha S, et al. Genetic polymorphisms and benzene metabolism in humans exposed to a wide range of air concentrations. *Pharmacogenet Genom*. 2007;17(10):789-801.
- Mansi A, Bruni R, Capone P, et al. Low occupational exposure to benzene in a petrochemical plant: modulating effect of genetic polymorphisms and smoking habit on the urinary t,t-MA/SPMA ratio. *Toxicol Lett.* 2012;213(1):57-62.
- Manini P, De Palma G, Andreoli R, et al. Occupational exposure to low levels of benzene: biomarkers of exposure and nucleic acid oxidation and their modulation by polymorphic xenobiotic metabolizing enzymes. *Toxicol Lett.* 2010;193(3):229-235.
- Nourozi MA, Neghab M, Bazzaz JT, Nejat S, Mansoori Y, Shahtaheri SJ. Association between polymorphism of GSTP1, GSTT1, GSTM1 and CYP2E1 genes and susceptibility to benzene-induced hematotoxicity. Arch Toxicol. 2018;92(6):1983-1990.
- 7. Ye LL, Zhang GH, Huang JW, et al. Are polymorphisms in metabolism protective or a risk for reduced white blood cell counts in a Chinese population with low occupational benzene exposures? *Int J Occup Environ Health.* 2015;21(3):232-240.
- 8. De Palma G, Manno M. Metabolic polymorphisms and biomarkers of effect in the biomonitoring of occupational exposure to low-levels of benzene: state of the art. *Toxicol Lett*. 2014;231(2):194-204.
- 9. Lan Q, Zhang L, Shen M, et al. Polymorphisms in cytokine and cellular adhesion molecule gene and susceptibility to hematotoxicity

among workers exposed to benzene. Cancer Res. 2005;65(20): 9574-9581.

- Carbonari D, Chiarella P, Mansi A, Pigini D, Iavicoli S, Tranfo G. Biomarkers of susceptibility following benzene exposure: influence of genetic polymorphisms on benzene metabolism and health effects. *Biomark Med.* 2016;10(2):145-163.
- Sun P, Zhang Z, Wan J, Zhao N, Jin X, Xia Z. Association of genetic polymorphisms in GADD45A, MDM2, and p14ARF with the risk of chronic benzene poisoning in a Chinese occupational population. *Toxicol Appl Pharmacol.* 2009;240(1):66-72.
- World Health Organization. Regional office for Europe. Air Quality Guidelines for Europe. 2nd ed.; Copenhagen: World Health Organization. Regional Office for Europe; 2000;1-273. https://apps.who.int/ iris/handle/10665/107335
- Wilbur S, Keith S, Faroon O, et al. Toxicological profile for benzene. Agency Toxic Subst Dis Regist. 2007;438:266-280.
- Safety and health legislation safety and health at work EU-OSHA [Internet]. [cited April 2021]. https://osha.europa.eu/en/safety-andhealth-legislation.
- 15. Great Britain: Health and Safety Executive. Workplace exposure limits: containing the list of workplace exposure limits for use with the ... control of substances hazardous to health regulations. Place of publication not identified: HSE Books; 2020.
- 16. EUR-Lex 31998L0024 EN EUR-Lex [Internet]. https://eur-lex. europa.eu/legal-content/EN/NIM/?uri=CELEX:31998L0024%20.
- 1910.1450 Occupational exposure to hazardous chemicals in laboratories. Occupational Safety and Health Administration [Internet]. [cited April 2021]: https://www.osha.gov/laws-regs/regulations/ standardnumber/1910/1910.1450.
- 18. Lan Q, Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. *Science*. 2004;306(5702):1774-1776.
- Garte S, Taioli E, Popov T, Bolognesi C, Farmer P, Merlo F. Genetic susceptibility to benzene toxicity in humans. J Toxicol Environ Health A. 2008;71(22):1482-1489. http://doi.org/10.1080/15287390802349974.
- Smith MT. Advances in understanding benzene health effects and susceptibility. Annu Rev Publ Health. 2010;31(1):133-148. http:// doi.org/10.1146/annurev.publhealth.012809.103646.
- Ross D. Functions and distribution of NQO1 in human bone marrow: potential clues to benzene toxicity. *Chem Biol Interact.* 2005;153– 154:137-146.
- Buthbumrung N, Mahidol C, Navasumrit P, et al. Oxidative DNA damage and influence of genetic polymorphisms among urban and rural schoolchildren exposed to benzene. *Chem Biol Interact.* 2008;172(3): 185-194.
- Dougherty D, Garte S, Barchowsky A, Zmuda J, Taioli E. NQO1, MPO, CYP2E1, GSTT1 and GSTM1 polymorphisms and biological effects of benzene exposure—a literature review. *Toxicol Lett.* 2008; 182(1):7-17.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339(1):b2535-b2535. http://doi.org/10. 1136/bmj.b2535.
- 25. Wells G, Shea B, Tetzlaff J. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses [Internet]. Ottawa Hospital Research Institute. 2014;1-4. http://www. ohri.ca/programs/clinical_epidemiology/oxford.asp
- Hosgood HD, Zhang L, Shen M, et al. Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity. *Occup Environ Med.* 2009;66(12):848-853.
- Xiao S, Gao L, Liu Y, et al. Association of genetic polymorphisms in ERCC1 and ERCC2/XPD with risk of chronic benzene poisoning in a Chinese occupational population. *Mutat Res Genet Toxicol Environ Mutagen*. 2013;751(1):52-58.
- Sun P, Qiu Y, Zhang Z, et al. Association of genetic polymorphisms, mRNA expression of p53 and p21 with chronic benzene poisoning in

a Chinese occupational population. *Cancer Epidemiol Biomarkers Prev.* 2009;18(6):1821-1828.

- Pesatori AC, Garte S, Popov T, et al. Early effects of low benzene exposure on blood cell counts in Bulgarian petrochemical workers/Effetti ematologici dell'esposizione a basse dosi di benzene in lavoratori petrolchimici bulgari. *Med Lav Work Environ Health*. 2009;100(2):83-90.
- 30. Torres CH, Varona ME, Lancheros A, Patiño RI, Groot H. DNA damage assessment and biological monitoring of occupational exposure to organic solvents, 2006. *Biomedica*. 2008;28(1): 126-138.
- Chanvaivit S, Navasumrit P, Hunsonti P, Autrup H, Ruchirawat M. Exposure assessment of benzene in Thai workers, DNA-repair capacity and influence of genetic polymorphisms. *Mutat Res Genet Toxicol Environ Mutagen*. 2007;626(1–2):79-87.
- Gu SY, Zhang ZB, Wan JX, Jin XP, Xia ZL. Genetic polymorphisms in CYP1A1, CYP2D6, UGT1A6, UGT1A7, and SULT1A1 genes and correlation with benzene exposure in a Chinese occupational population. J Toxicol Environ Health Part Curr Issues. 2007;70(11): 916-924.
- Wu F, Zhang Z, Wan J, et al. Genetic polymorphisms in hMTH1, hOGG1 and hMYH and risk of chronic benzene poisoning in a Chinese occupational population. *Toxicol Appl Pharmacol.* 2008;233(3): 447-453.
- 34. Zhang Z, Wan J, Jin X, et al. Genetic polymorphisms in XRCC1, APE1, ADPRT, XRCC2, and XRCC3 and risk of chronic benzene poisoning in a Chinese occupational population. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.* 2005;14 (11 Pt 1):2614-2619.
- Xue P, Gao L, Xiao S, et al. Genetic polymorphisms in XRCC1, CD3EAP, PPP1R13L, XPB, XPC, and XPF and the risk of chronic Benzene poisoning in a Chinese occupational population. Wei Q-Y, editor. PLOS One. 2015;10(12):e0144458.
- Mitri S, Fonseca ASA, Otero UB, Tabalipa MM, Moreira JC, Sarcinelli P d N. Metabolic polymorphisms and clinical findings related to Benzene poisoning detected in exposed Brazilian Gas-Station workers. Int J Environ Res Public Health. 2015;12(7):8434-8447.
- Xing C, Chen Q, Li G, et al. Microsomal epoxide hydrolase (EPHX1) polymorphisms are associated with aberrant promoter methylation of ERCC3 and hematotoxicity in benzene-exposed workers. *Environ Mol Mutagen*. 2013;54(6):397-405.
- Sun P, Qian J, Zhang Z-B. Polymorphisms in phase I and phase II metabolism genes and risk of chronic benzene poisoning in a Chinese occupational population. *Carcinogenesis*. 2008;29(12):2325-2329.
- Chen Y, Li G, Yin S, et al. Genetic polymorphisms involved in toxicant-metabolizing enzymes and the risk of chronic benzene poisoning in Chinese occupationally exposed populations. *Xenobiotica*. 2007;37(1):103-112.
- Shen M, Lan Q, Zang L, Chanok S, Lin G. Polymorphisms in genes involved in DNA double-strand break repair pathway and susceptibility to benzene-induced hematotoxicity. *Carcinogenesis*. 2006;27(10): 2083-2089.
- Lan Q, Zhang L, Min S, Jo W, Roel V, Li G. Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity – Johns Hopkins University. *Carcinogenesis*. 2009;30(1):50-58.
- Kim YJ, Choi JY, Paek D, Chung HW. Association of the NQO1, MPO, and XRCC1 polymorphisms and chromosome damage among workers at a petroleum refinery. J Toxicol Environ Health Part Curr Issues. 2008;71(5):333-341.
- Fang Y, Wu H-T, Ye Y-J, et al. Association between polymorphisms of metabolic enzyme genes and chromosomal damage in benzene-exposed workers in China. J Occup Environ Med. 2017;59(11):e215-e220.

- 44. Zhang GH, Ren JC, Luo M, et al. Association of BER and NER pathway polymorphism haplotypes and micronucleus frequencies with global DNA methylation in benzene-exposed workers of China: effects of DNA repair genes polymorphisms on genetic damage. *Mutat Res Genet Toxicol Environ Mutagen.* 2019;839:13-20.
- Carbonari D, Proietto A, Fioretti M, et al. Influence of genetic polymorphism on t,t-MA/S-PMA ratio in 301 benzene exposed subjects. *Toxicol Lett.* 2014;231(2):205-212.
- 46. Zhang GH, Lu Y, Ji BQ, et al. Do mutations in DNMT3A/3B affect global DNA hypomethylation among benzene-exposed workers in Southeast China?: effects of mutations in DNMT3A/3B on global DNA hypomethylation. *Environ Mol Mutagen.* 2017;58(9):678-687.
- Lin LC, Chen WJ, Chiung YM, Shih TS, Liao PC. Association between GST genetic polymorphism and dose-related production of urinary benzene metabolite markers, trans, trans-muconic acid and Sphenylmercapturic acid. *Cancer Epidemiol Biomarkers Prev.* 2008;17 (6):1460-1469.
- Qu Q, Shore R, Li G, et al. Biomarkers of benzene: urinary metabolites in relation to individual genotype and personal exposure. *Chem Biol Interact*. 2005;153–154:85-95.
- 49. Carrieri M, Bartolucci GB, Scapellato ML, et al. Influence of glutathione S-transferases polymorphisms on biological monitoring of exposure to low doses of benzene. *Toxicol Lett.* 2012;213(1): 63-68.
- Wan JX, Zhang ZB, Guan JR, et al. Genetic polymorphism of toxicantmetabolizing enzymes and prognosis of Chinese workers with chronic benzene poisoning. *Ann N Y Acad Sci.* 2006;1076:129-136.
- 51. Carrieri M, Spatari G, Tranfo G, et al. Biological monitoring of low level exposure to benzene in an oil refinery: effect of modulating factors. *Toxicol Lett.* 2018;298:70-75.
- 52. Zhang GH, Ye LL, Wang JW, et al. Effect of polymorphic metabolizing genes on micronucleus frequencies among benzene-exposed shoe workers in China. *Int J Hyg Environ Health*. 2013;217(7): 726-732.
- 53. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H: quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. *Genet Med.* 2002;4(2):62-70.
- Zarth AT, Murphy SE, Hecht SS. Benzene oxide is a substrate for glutathione S-transferases. *Chem Biol Interact.* 2015;242: 390-395.
- Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of populationscale sequencing projects. *Clin Pharmacol Ther.* 2017;102(4): 688-700.
- Zhang J, Zhu FY, Pu YP, et al. Analysis of multiple single nucleotide polymorphisms (SNPs) of myeloperoxidase (MPO) to screen for genetic markers associated with acute leukemia in Chinese Han population. J Toxicol Environ Health Part Curr Issues. 2007;70(11): 901-907.
- Wierda D, Irons RD. Hydroquinone and catechol reduce the frequency of progenitor B lymphocytes in mouse spleen and bone marrow. *Immunopharmacology*. 1982;4(1):41-54.
- Barreto G, Madureira D, Capani F, Aon-Bertolino L, Saraceno E, Alvarez-Giraldez LD. The role of catechols and free radicals in benzene toxicity: an oxidative DNA damage pathway. *Environ Mol Mutagen.* 2009;50(9):771-780.
- Brem R, Hall J. XRCC1 is required for DNA single-strand break repair in human cells|nucleic acids research | Oxford academic. *Nucleic Acids Res.* 2005;33(8):2512-2520.
- Fiebelkorn S, Meredith C. Estimation of the leukemia risk in human populations exposed to benzene from tobacco smoke using epidemiological data. *Risk Anal Off Publ Soc Risk Anal.* 2018;38(7):1490-1501.

61. Korte JE, Hertz-Picciotto I, Schulz MR, Ball LM, Duell EJ. The contribution of benzene to smoking-induced leukemia. *Environ Health Perspect*. 2000;108(4):333-339.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Ramírez-Lopera V, Uribe-Castro D, Bautista-Amorocho H, et al. The effects of genetic polymorphisms on benzene-exposed workers: A systematic review. *Health Sci Rep.* 2021;4:e327. <u>https://doi.org/10.1002/</u> <u>hsr2.327</u>